Aim: to evaluate long-term outcomes in patients treated with PEI for HCC Study data: 685 patients treated with 2147 treatments Conclusions: 5-, 10-, and 20-year survival rates were 49.0%, 17.9%, and 7.2%, respectively; PEI was potentially curative for HCC, resulting in OS of >20 years
Aim: to evaluate the effects of PEI or PAI in adults with early HCC Study data: three RCTs, 261 patients Conclusions: PEI and PAI do not differ significantly
Aim: to compare effects of PEI with other treatments in patients with liver metastasis Study data: one RCT, 48 patients Conclusions: addition of PEI to TACE does not confer clear benefit in survival
Aim: to compare effects of PEI with other treatments in patients with liver metastasis Study data: four RCTs, 652 patients Conclusions: RFA provides improved 3-year survival in patients with HCC, when compared to PEI
Aim: to compare effects of PEI with RFA in patients with small HCC Study data: five RCTs, 701 patients Conclusions: RFA is superior to PEI with respect to OS, DFS and 1-, 2-, and 3-year survival rates; RFA has better tumor response and smaller risk of local recurrence
Aim: to compare PEI with surgical resection in patients with small HCC Study data: 180 patients were randomized into two groups Conclusions: chemical ablation is less invasive and as effective as surgical resection
Aim: to compare PEI + TACE with PEI alone in patients with small HCC Study data: 52 patients were randomized into two groups Conclusions: combined PEI + TACE is superior to PEI alone in the treatment of patients with HCC tumors measuring <2 cm in greatest dimension
Aim: to evaluate effects of PEI in patients with liver metastasis Study data: review of multiple studies Conclusions: PEI is effective in only a selected group of patients with small metastases from colorectal, mammary, and endocrine tumors when surgery is contraindicated
